Identification of an Orally Bioavailable, Brain-Penetrant Compound with Selectivity for the Cannabinoid Type 2...

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Pharmacology

Background:

• The endocannabinoid system (ECS) plays a crucial role in various pathophysiological processes.
• The CB2 receptor subtype, primarily found on immune cells like microglia, exerts anti-inflammatory effects in the central nervous system.

Purpose of the Study:

• To identify novel chemotypes that selectively modulate the CB2 receptor.
• To synthesize and evaluate Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) as potential CB2 receptor ligands.

Main Methods:

• Synthesis of 17 (S,E)-11-[2-(arylmethylene)hydrazono]-PBD analogs.
• Competitive [3H]CP-55,940 binding assays to assess receptor affinity.
• Concentration-response analysis for selectivity and potency determination.
• Pharmacokinetic studies (oral and intravenous) of lead compound 4k.

Main Results:

• Five PBD analogs demonstrated significant displacement of [3H]CP-55,940 at 10 μM.
• Compounds 4k and 4q emerged as potent and selective CB2 ligands with sub-micromolar inhibitory constants (Ki).
• Compound 4k exhibited oral bioavailability, achieving substantial brain concentrations and favorable elimination half-lives.

Conclusions:

• Pyrrolo[2,1-c][1,4]benzodiazepines represent a novel chemotype for selective CB2 receptor modulation.
• Compounds 4k and 4q hold promise as starting points for developing therapeutics targeting the CB2 receptor.
• Further optimization of these novel compounds could lead to enhanced affinity and selectivity for therapeutic applications.